BIOSIMILARS MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION Biosimilars Market - Overview Biosimilars Market, by Drug Class (Recombinant Human Growth Hormone, Granulocyte ColonyStimulating Factor, Insulin, Anticoagulants, Fusion Proteins, Erythropoietin, Monoclonal Antibodies, Follitropin, and Others), by Therapy Type (Oncology, Immunology, Hematology, Hormone Therapy, Metabolic Disorders, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Specialty Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2018-2026 Global Biosimilars Market, by Drug Class (Recombinant Human Growth Hormone, Granulocyte Colony-Stimulating Factor, Insulin, Anticoagulants, Fusion Proteins, Erythropoietin, Monoclonal Antibodies, Follitropin, and Others), by Therapy Type (Oncology, Immunology, Hematology, Hormone Therapy, Metabolic Disorders, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Specialty Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 5.0 billion in 2017, and is projected to exhibit a CAGR of 35.2% over the forecast period (2018 - 2026). Demand for biosimilars is increasing in healthcare sectors in comparison to small molecules due to the low manufacturing cost of biosimilars. Biosimilars are less expensive to produce than reference biologics. For instance, as per a National Center for Biotechnology 2017 study, biosimilars generally require 8 to 10 years to develop at a cost between US$ 100 and US$ 200 million, compared to around US$ 2.5 billion for developing a new drug.
Browse Research Reports: https://www.coherentmarketinsights.com/marketinsight/biosimilars-market-750 Š Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION An increasing number of manufacturers engaged in developing biosimilars that are similar to current analogs at more affordable prices. The low cost and effectiveness of biosimilar insulin are aiding in the treatment of patients suffering from diabetes mellitus. Major investments by regional players for research and development of biosimilar production is expected to drive the growth of the market in emerging economies. For instance, in October 2016, Cipla Inc. invested US$ 8 million to set up a manufacturing plants for biosimilars in South Africa. International players are collaborating with local players in emerging economies to enhance their market share. For instance, Mylan N.V. has a long-standing biosimilars partnership with India-based Biocon. Browse 27 Market Data Tables and 21 Figures spread through 231 Pages and in-depth TOC on " Global Biosimilars Market, by Drug Class (Recombinant Human Growth Hormone, Granulocyte Colony-Stimulating Factor, Insulin, Anticoagulants, Fusion Proteins, Erythropoietin, Monoclonal Antibodies, Follitropin, and Others), by Therapy Type (Oncology, Immunology, Hematology, Hormone Therapy, Metabolic Disorders, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Specialty Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026" Moreover, several manufacturing companies are expected to lose patent protection for various drugs. For instance, LEVEMIR, an Insulin by Novo Nordisk is expected to lose its patent rights in 2019. Request a Sample copy of this reports : https://www.coherentmarketinsights.com/insight/request-sample/750 Š Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION Such instances are creating opportunities for pharmaceutical manufacturers to develop alternatives to the patents. Furthermore, expiry and termination of pharmaceuticals drugs such as Humira, Enbrel, and Remicade is offering significant opportunity for new players to enter in the market. Key Takeaways of the Biosimilars Market: The global biosimilars market is expected to witness a CAGR of 35.2% during the forecast period (2018–2026), owing to increasing approvals of biosimilars
Among drug class, the monoclonal antibodies segment is expected to account for major revenue share in the market over the forecast period. The development of monoclonal antibodies biosimilars — a major therapeutic class for diseases including various cancers and autoimmune disorders such as rheumatoid arthritis — is accelerating rapidly, owing to the upcoming patent expiry of top-selling drugs. Major players operating in the global biosimilars market include, Novartis AG, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Celltrion Healthcare Co., Ltd., Biocon Limited, Amgen, Inc., Dr. Reddy's Laboratories, and Sanofi S.A. Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/750 © Coherent market Insights. All Rights Reserved
ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele.
SERVICES INDUSTRY ANALYSIS
CUSTOMIZED RESEARCH
SYNDICATED RESEARCH
MARKET INTELLIGENCE SERVICES
CONSULT STUDIES
COUNTRY SPECIFIC STUDIES
Š Coherent market Insights. All Rights Reserved
ABOUT CMI SECTOR COVERAGE
BIOTECHNOLOGY
CLINICAL DIAGNOSTIC
HEALTHCARE IT
MEDICAL DEVICES
MEDICAL IMAGING
PHARMACEUTICAL
OUR CLIENTS
Global Leading Equipment and System Manufacturers Marketing Consultancies and the Advertising Industry Component Providers and System Integrators
Private and Government organization
Distributors, Retailors and Value Added Resellers
Outsourcing Companies
Healthcare IT Solutions Developers
Universities and Business Schools.
© Coherent market Insights. All Rights Reserved
KEY STATS
RESEARCH SOLUTIONS
100+
FEASIBILITY STUDIES
Insights Published Per Year
GLOBAL REPORTS
150+
Consulting Projects Till Date
COUNTRY ANALYSIS CONSULT PROJECTS
125+
Clients Worldwide Per Year
110+
SURVEY RESEARCH
EXCEL FORECAST DATABASE
CUSTOMIZED SOLUTIONS
COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS
Analysts and Contract Consultants
Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved
THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702
Š Coherent market Insights. All Rights Reserved